Long-term follow-up of AL-001 eye injection in wet macular degeneration
Follows people with wet macular degeneration who previously received AL-001 by eye injection.
Plain-language title generated from the registry record
Registry title: Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with wet age-related macular degeneration who already received AL-001 eye injection in an earlier study. It follows them over a long time.
- Age
- 50 years and older
- Sex
- All sexes can join.
- Earlier treatment
- Must have been in an AL-001 study and received the AL-001 eye injection.
Read by machine on 9 November 2026.
Where in China
- Chinese Academy of Medical Sciences & Peking Union HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Anlong Biopharmaceutical Co., Ltd.
- Trial code
- NCT06718816
- Record updated
- 5 December 2024
- Original description
This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.Read full original descriptionShow less
A Long-term Follow-up Study to Evaluate the Safety and Effectivity of AL-001 Ophthalmic Injection in Subjects with Wet Age-related Mecular Degeneration (wAMD)
This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.
Inclusion: The subjects enrolled in AL-001 study and received AL-001 ophthalmic injection; The subject or their legal representative agrees to participate in this study and signs a written ICF; The subjects are willing and able to follow planned visits and procedures.
Exclusion: None.